Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (253) Acyclovir Capsules, Teva Pharmaceutical,
...Newly Approved Drug Therapies (253) Acyclovir Capsules, Teva Pharmaceutical, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Acyclovir Capsules Company: Teva Pharmaceutical Approval Status: Approved April 1997 Treatment Area: anti-viral treatment General ...
View Page

2.  Newly Approved Drug Therapies (1056) Zirgan (ganciclovir ophthalmic gel), Sirion Therapeutics,
...randomized, controlled, multicenter clinical trial enrolled 164 subjects with herpetic keratitis. Zirgan was compared to acyclovir ophthalmic ointment 3% and evaluated for non-inferiority. Zirgan was determined to be non-inferior to acyclovir ophthalmic ointment. Clinical resolution (healed ulcers) at Day 7 was achieved in 77% of the ...
View Page

3.  Newly Approved Drug Therapies (18) Valtrex (valacyclovir HCl), GlaxoSmithKline,
...headache, nausea, diarrhea, and dizziness. Mechanism of Action Valtrex is rapidly and extensively converted to acyclovir after oral administration. The drug delivers three to five times higher blood levels of acyclovir than oral Zovirax. Additional Information As many as 31 million Americans are infected with the ...
View Page

4.  Study Posting (2348) Trial #94809, Herpes Simplex Infections, New York, NY
...one month prior to or at screening. Intercourse within 48 hours of enrollment. Hypersensitivity to acyclovir. Julia B Epstein, FNP Mount Sinai Medical Center One Gustave L. Levy Place New York ...
View Page

5.  Study Posting (2348) Trial #94802, Herpes Simplex Infections, New York, NY
...one month prior to or at screening. Intercourse within 48 hours of enrollment. Hypersensitivity to acyclovir. Julia B Epstein, FNP Mount Sinai Medical Center One Gustave L. Levy Place New York ...
View Page

6.  Study Posting (4519) Trial #124464, Cytomegalovirus Infections, Pittsburgh, PA
...regimens (>=4 days) prior to pharmacokinetic assessments. Exclusion Criteria: • history of any adverse reaction to acyclovir, valacyclovir, ganciclovir or valganciclovir; • evidence of graft rejection; • patient has received anti-CMV prophylaxis with ...
View Page

7.  Study Posting (4519) Trial #124246, Cytomegalovirus Infections, Cleveland, OH
...regimens (>=4 days) prior to pharmacokinetic assessments. Exclusion Criteria: • history of any adverse reaction to acyclovir, valacyclovir, ganciclovir or valganciclovir; • evidence of graft rejection; • patient has received anti-CMV prophylaxis with ...
View Page

8.  Study Posting (4519) Trial #123579, Cytomegalovirus Infections, Durham, NC
...regimens (>=4 days) prior to pharmacokinetic assessments. Exclusion Criteria: • history of any adverse reaction to acyclovir, valacyclovir, ganciclovir or valganciclovir; • evidence of graft rejection; • patient has received anti-CMV prophylaxis with ...
View Page

9.  Study Posting (4519) Trial #123966, Cytomegalovirus Infections, Los Angeles, CA
...regimens (>=4 days) prior to pharmacokinetic assessments. Exclusion Criteria: • history of any adverse reaction to acyclovir, valacyclovir, ganciclovir or valganciclovir; • evidence of graft rejection; • patient has received anti-CMV prophylaxis with ...
View Page

10.  CenterWatch: New Medical Therapies in Disease Category (372), Vaccines
...this time. Transport Pharmaceuticals announced positive results from a phase IIb trial of device-enhanced acyclovir for the treatment of herpes labialis. This multi-center, randomized, double blind, placebo-controlled, clinic ...
View Page

11.  CenterWatch: New Medical Therapies in Disease Category (179), HIV Infections
...this time. Transport Pharmaceuticals announced positive results from a phase IIb trial of device-enhanced acyclovir for the treatment of herpes labialis. This multi-center, randomized, double blind, placebo-controlled, clinic ...
View Page

12.  CenterWatch: New Medical Therapies in Disease Category (465), Bacterial Infections
...this time. Transport Pharmaceuticals announced positive results from a phase IIb trial of device-enhanced acyclovir for the treatment of herpes labialis. This multi-center, randomized, double blind, placebo-controlled, clinic ...
View Page

13.  CenterWatch: New Medical Therapies in Disease Category (295), Cold Sores (Herpes Labialis Infections)
...this time. Transport Pharmaceuticals announced positive results from a phase IIb trial of device-enhanced acyclovir for the treatment of herpes labialis. This multi-center, randomized, double blind, placebo-controlled, clinic ...
View Page

14.  CenterWatch: Immunology/Infectious Diseases Approved Drug Therapies
...Beecham; Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997 Acyclovir Capsules ; Teva Pharmaceutical; Generic equivalent of Zovirax, Approved April 1997 Aldara (imiquimod) ; 3M Pharmaceuticals; Treatment ...
View Page

15.  CenterWatch: List of Newly Approved Drug Thearapies
...Beecham; Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997 Acyclovir Capsules ; Teva Pharmaceutical; Generic equivalent of Zovirax, Approved April 1997 Aldara (imiquimod) ; 3M Pharmaceuticals; Treatment ...
View Page

16. Clinical Trial Results by Drug Names
...treatment and neutropenia in prophylactic doses in the following cycles. All patients received cotrimoxazole and acyclovir prophylaxis. There were no deaths during the application of chemotherapy on study. A total of ...
View Page

17.  Study Posting (180) Trial #81802, Pancreatic Cancer, New York, NY
...informed consent or intensive treatment (e.g. serious infection). • Absence of concurrent treatment with cholestyramine, acyclovir, cyclosporine, or antacids with magnesium or aluminum hydroxides because of their effects on drug metabolism ...
View Page